Nirmatrelvir not checked

Pfizer · PF-07321332 · PF-07321332/ritonavir

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
None yet
 
Trials
4 active
19 in total · 5 in the EU

What this is

How it works
How it works isn't classified yet
Tested for
COVID-19
Main trialPhase 3
“The purpose of this clinical trial is to learn about the safety, pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and eliminated from your body after you take it), and efficacy (how well a study treatment works in the study) of the study medicine (called nirmatrelvir/ritonavir) for potential treatment of coronavirus disease 2019 (COVID-19). The study medicine will be given to patients under 18 years of age with COVID-19 that are not hospitalized but are at risk for severe disease.”In the company’s words, NCT05261139 on ClinicalTrials.gov
Other names
PF-07321332 · Paxlovid · PF-07321332/ritonavir

Other drugs for COVID-19

All 43 drugs for COVID-19

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials19

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 30 Jul 2026 EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
Phase 2/3Completed 9 Dec 2021 EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19
Phase 2/3Completed 12 Apr 2022 A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
Phase 2/3Terminated 25 Jul 2022 Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).
Phase 2Completed 17 Jul 2023 A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System
Phase 2Withdrawn 21 Sep 2023 A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19
Phase 2Completed 27 Sep 2023 A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir
Phase 1Completed 1 Sep 2021 STUDY OF PF-07321332 IN HEALTHY PARTICIPANTS
Phase 1Completed 9 Oct 2021 Drug-Drug Interaction Study Assessing Effect of Carbamazepine on PF-07321332 Boosted With Ritonavir
Phase 1Completed 7 Dec 2021 Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332
Phase 1Withdrawn 1 Apr 2022 Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]PF-07321332 in Healthy Male Participants.
Phase 1Completed 16 May 2022 Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation
Phase 1Terminated 11 Jul 2023 A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
Phase 1Completed 15 Dec 2023 A Study to Learn About the Medicine (PF-07321332 or Nirmatrelvir/Ritonavir) in Healthy Lactating Women
Phase 1Terminated 26 Mar 2025 A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19
Phase 2Authorised not given OPtimisation of antiviral Therapy in Immunocompromised COVID-19 patients: a randomized factorial controlled strategy trial: the OPTICOV Study
Phase 3Authorised not given Paxlovid long covid-19 prevention trial with recruitment in the community in Norway
Phase 4Ended not given TURN-COVID Biobank: The Dutch cohort study tor the evaluation of the use of neutralizing monoclonal antibodies and other antiviral agents against SARS-CoV-2
Phase 2Authorised not given Achieving viral CLEARance in immunocompromised participants with long-term persistence of SARS-CoV-2 - an open-label randomized trial (CLEAR)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow Nirmatrelvir

Following is part of Solo: you see every change to Nirmatrelvir the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in